We are live on
!
Find out more
EC
Euclidean Capital Portfolio holdings
AUM
$392M
1-Year Est. Return
31.85%
This Fund
S&P 500
This Quarter
Est. Return
-25.01%
1 Year Est. Return
+31.85%
3 Year Est. Return
+76.27%
5 Year Est. Return
-20.16%
10 Year Est. Return
–
AUM
$299M
AUM Growth
-$174M
(-37%)
Cap. Flow
-$27.1M
Cap. Flow
% of AUM
-9.05%
Top 10 Holdings %
Top 10 Hldgs %
99.08%
Holding
14
New
4
Increased
–
Reduced
2
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Beam Therapeutics
BEAM
|
+$2.96M |
| 2 |
Vir Biotechnology
VIR
|
+$1.39M |
| 3 |
Pinduoduo
PDD
|
+$1.38M |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$187K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
|
+$16.5M |
| 2 |
Oric Pharmaceuticals
ORIC
|
+$12.8M |
| 3 |
Revolution Medicines
RVMD
|
+$3.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.24% |
| 2 | Financials | 1.39% |
| 3 | Consumer Discretionary | 0.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PMV Pharmaceuticals
PMVP
$59.2M
| $137M | 45.99% |
4,179,416
| – | – |
|
|
NGM
2
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $43.4M | 14.53% |
1,493,349
-590,253
| -28% | -$16.5M |
|
|
3
Oric Pharmaceuticals
ORIC
$1.15B
| $24.4M | 8.17% |
996,734
-403,701
| -29% | -$12.8M |
|
4
Alector
ALEC
$168M
| $19.8M | 6.61% |
980,894
| – | – |
|
5
Denali Therapeutics
DNLI
$3.65B
| $18.5M | 6.19% |
323,749
| – | – |
|
6
Foghorn Therapeutics
FHTX
$266M
| $16.6M | 5.56% |
1,261,261
| – | – |
|
|
RAPT
7
DELISTED
RAPT Therapeutics
RAPT
| $16.3M | 5.47% |
91,975
| – | – |
|
|
CNST
8
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $13M | 4.34% |
554,325
| – | – |
|
9
First Financial Bancorp
FFBC
$3.55B
| $4.17M | 1.39% |
173,576
| – | – |
|
|
10
Beam Therapeutics
BEAM
$2.63B
| $2.49M | 0.83% |
+31,131
| New | +$2.96M |
|
|
11
Vir Biotechnology
VIR
$1.46B
| $1.33M | 0.44% |
+25,864
| New | +$1.39M |
|
|
12
Pinduoduo
PDD
$126B
| $1.09M | 0.37% |
+8,174
| New | +$1.38M |
|
|
RUBY
13
DELISTED
Rubius Therapeutics, Inc
RUBY
| $339K | 0.11% |
+12,791
| New | +$187K |
|
|
14
Revolution Medicines
RVMD
$39.9B
| – | – |
-93,436
| Closed | -$3.7M |
|
Similar funds
WSC
RC
DCM
HBWM
BWM
IPW
TCM
MA
Euclidean Capital's Q1 2021 Portfolio in Review
As of Q1 2021, Euclidean Capital held 14 positions worth $299M, down 37% from $472M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Euclidean Capital withdrew a net $27.1M in Q1 2021, closing 1 position and reducing 2 holdings. Its most notable exit was Revolution Medicines, an estimated $3.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Euclidean Capital opened a new position in Beam Therapeutics worth $2.49M.
- Euclidean Capital's largest Q1 2021 buy was Beam Therapeutics: 31,131 shares worth $2.49M.
- Euclidean Capital's biggest Q1 2021 reduction was NGM Biopharmaceuticals, Inc. Common Stock, cutting an estimated $16.5M.
- Euclidean Capital fully exited Revolution Medicines in Q1 2021, selling an estimated $3.7M.
- Euclidean Capital's ten largest holdings make up 99% of its $299M portfolio in Q1 2021.
- Euclidean Capital opened 4 new positions and closed 1 in Q1 2021.
- Euclidean Capital's portfolio value fell 37% quarter-over-quarter to $299M.
Based on Euclidean Capital's 13F filing for Q1 2021, filed 17 May 2021.